ST. LOUIS, May 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today introduced Precisio(TM) Kinases (www.sigma.com/precisiokinases), a new collection of high quality active kinases that is expected to enable scientists to achieve greater insight into protein phosphorylation and cell signaling. Optimized for high-throughput kinase screening and profiling, Precisio Kinases allow for the characterization of cellular processes and may contribute to new therapeutic strategies for treating diseases including cancer, diabetes and hypertension.
"Precisio Kinases are engineered to have the quality and consistency scientists demand for high-throughput applications," said Helge Bastian, Vice President of Marketing and Business Development at Sigma-Aldrich. "Combined with Sigma's existing product lineup for kinase and phosphatase research, this new offering facilitates a greater understanding of signaling pathways and may provide the foundation for new drug and therapeutic targets."
Protein kinases are essential in intercellular communication, mediating signal transduction in development, transcription, immune response, metabolism, apoptosis and cell differentiation. Improper kinase function plays a role in many diseases, most notably cancer, and the study of these proteins and their functions may contribute to the discovery and development of new drug targets.
Sigma-Aldrich's new Precisio Kinases are suitable for high throughput screening and profiling. Each Precisio Kinase contains a batch-optimized assay protocol, ensuring high performance, quick implementation and consistent results in a variety of applications.
The Precisio Kinases complement Sigma-Aldrich's existing offerings in the field of kinase and phosphatase rese
|SOURCE Sigma-Aldrich Corporation|
Copyright©2009 PR Newswire.
All rights reserved